MAS
AXSM icon

Meeder Advisory Services’s Axsome Therapeutics AXSM Stock Holding History

Meeder Advisory Services’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$311K Sell
1,272
-1
-0.1% -$217 0.01% 544
2026
Q1 		$215K Buy
1,273
+128
+11% +$22.1K 0.01% 635
2025
Q4 		$209K Buy
+1,145
New +$160K 0.01% 636

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Meeder Advisory Services's AXSM Position: Q2 2026 in Review

Meeder Advisory Services reduced its Axsome Therapeutics (AXSM) stake by 0.08% in Q2 2026, selling an estimated $217 and leaving 1,272 shares worth $311K. The position accounts for 0.01% of the portfolio, ranked #544.

Meeder Advisory Services first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Meeder Advisory Services held 1,272 shares of Axsome Therapeutics worth $311K as of Q2 2026.
  • Meeder Advisory Services sold 1 Axsome Therapeutics share in Q2 2026, an estimated $217.
  • Axsome Therapeutics made up 0.01% of Meeder Advisory Services's portfolio in Q2 2026, its #544 holding.
  • Meeder Advisory Services first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Meeder Advisory Services's 13F filing for Q2 2026, filed 7 Aug 2026.